Phase I/II clinical trial of gene therapy for hormone refractory metastatic prostate cancer

被引：0
|
作者：
Gotoh, A [1 ]
Terao, S [1 ]
Shirakawa, T [1 ]
机构：
[1] Kobe Univ, Sch Med, Int Ctr Med Res & Treatment, Kobe, Hyogo 6500017, Japan
来源：
JOURNAL OF GENE MEDICINE | 2006年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：371 / 372
页数：2
相关论文
共 50 条
  • [1] Phase II trial of paclitaxel in front-line therapy of hormone refractory metastatic prostate cancer
    Kolevska, T.
    Goldstein, D.
    Davis, C.
    Fehrenbacher, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Rhodamine-123: Therapy for hormone refractory prostate cancer, a phase I clinical trial
    Jones, LW
    Narayan, KS
    Shapiro, CE
    Sweatman, TW
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (04) : 435 - 440
  • [3] Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer
    Shirakawa, Toshiro
    Terao, Shuji
    Hinata, Nobuyuki
    Tanaka, Kazushi
    Takenaka, Atsushi
    Hara, Isao
    Sugimura, Kazuro
    Matsuo, Masafumi
    Hamada, Katsuyuki
    Fuji, Kohzo
    Okegawa, Takatsugu
    Higashihara, Eiji
    Gardner, Thomas A.
    Kao, Chinghai
    Chung, Leland W. K.
    Kamidono, Sadao
    Fujisawa, Masato
    Gotoh, Akinobu
    HUMAN GENE THERAPY, 2007, 18 (12) : 1225 - 1232
  • [4] A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
    Dreicer, R
    Kemp, JD
    Stegink, LD
    Cardillo, T
    Davis, CS
    Forest, PK
    See, WA
    CANCER INVESTIGATION, 1997, 15 (04) : 311 - 317
  • [5] A phase II trial of lapatinib in hormone refractory prostate cancer
    Whang, Y. E.
    Moore, C. N.
    Armstrong, A. J.
    Rathmell, W. K.
    Godley, P. A.
    Crane, J. M.
    Grigson, G. I.
    Morris, K.
    Watkins, C. P.
    George, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
    Kumar Rajagopalan
    David Peereboom
    G. Thomas Budd
    Thomas Olencki
    Siva Murthy
    Paul Elson
    Denise McLain
    Ronald Bukowski
    Investigational New Drugs, 1998, 16 : 255 - 258
  • [7] Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
    Rajagopalan, K
    Peereboom, D
    Budd, GT
    Olencki, T
    Murthy, S
    Elson, P
    McLain, D
    Bukowski, R
    INVESTIGATIONAL NEW DRUGS, 1998, 16 (03) : 255 - 258
  • [8] Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC)
    Kolevska, T.
    Ryan, C. J.
    Huey, V.
    Weisberg, L.
    Wang, S.
    Baer, D.
    Ghadialy, A.
    Goldstein, D.
    Fireman, B.
    Fehrenbacher, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
    Small, Eric J.
    Fontana, Joseph
    Tannir, Nizar
    DiPaola, Robert S.
    Wilding, George
    Rubin, Mark
    Iacona, Renee Bailey
    Kabbinavar, Fairooz F.
    BJU INTERNATIONAL, 2007, 100 (04) : 765 - 769
  • [10] A phase II trial of irinotecan in hormone-refractory prostate cancer
    Reese, DM
    Tchekmedyian, S
    Chapman, Y
    Prager, D
    Rosen, PJ
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 353 - 359
12345